Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PAM | P19021 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15467725 | 0.96 | CYP4Z1 (0.41) | CYP4Z1GPR84ALDH1A1KMT2AMEN1 | |
| SCHEMBL15471774 | 0.84 | CYP4Z1 (0.46) | CYP4Z1ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL30349563 | 0.84 | CYP4F2 (0.45) | GPR84ALDH1A1KMT2AMEN1 | |
| SCHEMBL15474134 | 0.83 | ALDH1A1 (0.46) | CYP4Z1ALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL13902231 | 0.80 | CYP4Z1 (0.51) | CYP4Z1ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL15474135 | 0.80 | CYP4Z1 (0.43) | CYP4Z1ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL11926723 | 0.78 | GLA (0.45) | CYP4Z1ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL8490662 | 0.77 | KMT2A (0.55) | GPR84ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL6179185 | 0.76 | AKR1B1 (0.54) | GPR84KMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL1332625 | 0.76 | ALDH1A1 (0.68) | CYP4Z1ALDH1A1KMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4142732-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143178-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001070738-A2 | TRI-ARYL-SUBSTITUTED-ETHANE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | disclosed |
| EP-0714393-B1 | THIAZOLES AS ANTIVIRAL | PFIZER (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5789408-A | Antiviral thiazoles | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0714393-A1 | THIAZOLES AS ANTIVIRAL | PFIZER INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005378-A1 | ANTIVIRAL THIAZOLES | PFIZER INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| EP-0394476-A1 | NOVEL 1,3,4-THIADIAZOLE DERIVATIVES AND ANTIULCER AGENTS CONTAINING SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | CYP4Z1 4228/4885GPR84 3975/4885ALDH1A1 918/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | CYP4Z1 4485/4885GPR84 4111/4885ALDH1A1 1674/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | CYP4Z1 4485/4885GPR84 4111/4885ALDH1A1 1674/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | CYP4Z1 4485/4885GPR84 4111/4885ALDH1A1 1674/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | CYP4Z1 4485/4885GPR84 4111/4885ALDH1A1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.